홈 카테고리 맞춤형시장조사 국제컨퍼런스 글로벌 파트너 메일링 서비스 회사소개회사소개 Contact Us
English Japaness Chinese
Home > 시장보고서 > 바이오테크놀러지 > 바이오장비 > Biologic Imaging Reagents: Technologies and Global Markets
카테고리
바이오테크놀러지 (1590)
게놈 창약 (202)
맞춤형의료 (51)
바이오마커 (154)
바이오매트리얼 (54)
바이오장비 (357)
분자표적치료(MTT) (131)
유전자 치료/RNAi (101)
재생의학 (124)
항체/면역 (191)
시장보고서

Biologic Imaging Reagents: Technologies and Global Markets

리서치사 BCC Research
발행일 2009년 01월 상품코드 78812
페이지 정보 219 pages
가격
US $ 4,850 ￦ 5,778,700 PDF by E-mail (Single User License)
US $ 5,950 ￦ 7,089,400 PDF by E-mail (Business Unit License)
US $ 8,500 ￦ 10,127,700 PDF by E-mail (Enterprise License)


영문목차

Abstract

HIGHLIGHTS

This report:

  • Describes various imaging reagent types including optical probes and dyes, imaging nanomaterials, supermolecules, contrast agents and radiopharmaceuticals
  • Provides market forecasts to determine the global market and future demand growth for biologic imaging reagents over a 5-year period, from 2008 to 2013
  • Evaluates future growth opportunities in imaging reagents for life science companies
  • Provides a comprehensive discussion of where state-of-the-art is in biologic imaging reagents and forecasts the future market potential for key market segments
  • Includes company profiles and industry alliances.

SCOPE OF REPORT

The study scope includes the biologic imaging reagents that are commercial or likely to be commercialized within the next five years. Fluorescent probes and dyes, imaging nanomaterials (including quantum dots and other nanoparticles), fluorescent proteins; supermolecules; contrast reagents for MRI, x-ray and ultrasound, and imaging radiopharmaceuticals are studied. Both the in-vivo and in-vitro market segments are included. Each technology is analyzed to determine its market status, impact on future market segments, and forecasted growth from 2008 through 2013. Technology status and market driving forces are also discussed.

BCC examines imaging reagent producers and the industry structure in specialized segments of the industry. We also review industry alliances and acquisitions, and the use of biologic imaging reagents in key diagnostics and R&D tools platforms including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis. The markets for novel biologic imaging reagent applications, including targeted multifunctional and hybrid therapeutic reagents are analyzed, and the main companies in these fields are highlighted.

METHODOLOGY

BCC surveyed key users and producers in each of the end user market segments and technology fields that will be commercially important during the next five years. Discussions with industry thought leaders, as well as secondary market research was performed.

Based on our analysis, we project the future applications of biologic imaging reagents in the major end user market segments and by technology type, and forecast sales revenues for 2008 through 2013.

INFORMATION SOURCES

BCC surveyed academic, government and industrial institutions to obtain data for this study. Included were life science research tools, pharmaceutical, diagnostic, biotechnology and nanotechnology firms, and leading life science research institutions. We also spoke with leading industry thought leaders. In addition, we compiled data from secondary sources including industry, trade, and government.

Table of Contents

CHAPTER ONE: INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE OF REPORT
  • METHODOLOGY
  • INFORMATION SOURCES
  • RELATED BCC REPORTS
  • ANALYST CREDENTIALS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER TWO: SUMMARY

  • SUMMARY TABLE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TYPE, THROUGH 2013 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TYPE, 2006-2013 ($ MILLIONS)
  • SUMMARY (CONTINUED)

CHAPTER THREE: OVERVIEW

  • INTRODUCTION
  • BIOLOGIC IMAGING TECHNOLOGIES COVERED IN THIS REPORT
    • TABLE 1 SCOPE OF THIS REPORT
  • MARKET POTENTIAL OF BIOLOGIC REAGENTS PRODUCTS
    • TABLE 2 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY, THROUGH 2013 ($ MILLIONS)
    • TABLE 3 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET, THROUGH 2013 ($ MILLIONS)
  • FORCES DRIVING BIOLOGIC IMAGING REAGENTS INDUSTRY GROWTH
    • TABLE 4 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES
  • FORCES DRIVING BIOLOGIC ..... (CONTINUED)
  • LIFE CYCLE STATUS OF BIOLOGIC IMAGING REAGENTS TECHNOLOGIES
    • TABLE 5 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS
  • THE BIOLOGIC IMAGING REAGENTS INDUSTRY
    • TABLE 6 BIOLOGIC IMAGING REAGENTS KEY COMPETITORS
  • THE BIOLOGIC IMAGING REAGENTS ..... (CONTINUED)

CHAPTER FOUR: BIOLOGIC IMAGING TECHNOLOGIES

  • IMAGING REAGENT TYPES
    • TABLE 7 KEY BIOLOGIC IMAGING REAGENT TYPES
  • IN-VIVO IMAGING MODALITIES
    • TABLE 8 IN-VIVO IMAGING MODALITIES
    • TABLE 9 COMPARISON OF IN-VIVO IMAGING MODALITIES
  • IN-VIVO IMAGING MODALITIES (CONTINUED)
  • MOLECULAR IMAGING
  • IN-VITRO IMAGING/DETECTION
    • TABLE 10 APPLICATIONS OF IN-VITRO BIOLOGIC IMAGING
  • TRENDS IN IN-VIVO IMAGING
    • TABLE 11 KEY TRENDS FOR IN-VIVO IMAGING
  • TRENDS IN IN-VIVO IMAGING (CONTINUED)
  • BIOLOGIC IMAGING REAGENTS TECHNOLOGIES
  • NANOPARTICLES
    • TABLE 12 NANOPARTICLES IN IMAGING APPLICATIONS
  • Nanoparticles (Continued)
    • TABLE 13 COMPARISON OF ANTIBODY CONJUGATE NANOPARTICLES
  • FLUORESCENT DYES AND PROBES
    • TABLE 14 FLUORESCENT DYES AND PROBES
  • Fluorescent Dyes and Probes (Continued)
    • TABLE 15 ADVANTAGES OF FLUORESCENCE VERSUS TRADITIONAL METHODS
    • TABLE 16 FLUORESCENT DYE PERFORMANCE CRITERIA
  • FLUORESCENT PROTEINS
    • TABLE 17 TYPES OF FLUORESCENT PROTEINS
  • Fluorescent Proteins (Continued)
  • Genetically Engineering Fluorescent Proteins
    • TABLE 18 PHOTOACTIVABLE AND PHOTOCONVERTIBLE FLUORESCENT PROTEIN TYPES
  • Engineered Fluorescent Cell Lines
  • Emerging Fluorescent Protein Applications
    • TABLE 19 EMERGING APPLICATIONS OF FLUORESCENT PROTEINS
  • Comparison of Fluorescent Proteins with Fluorescent Dyes
    • TABLE 20 FLUORESCENT PROTEINS VERSUS DYES
  • Technology Challenges
    • TABLE 21 TECHNOLOGY CHALLENGES FOR FLUORESCENT PROTEINS
  • SUPERMOLECULES
    • TABLE 22 CLASSIFICATION OF IMAGING SUPERMOLECULES
  • SUPERMOLECULES (Continued)
    • FIGURE 1 MOLECULAR ENGINEERING OF DENDRIMER IMAGING SUPERMOLECULES
  • QUANTUM DOTS
    • TABLE 23 COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENT PROTEINS
    • FIGURE 2 QUANTUM DOT SPECTRA
    • FIGURE 3 FLUORESCENT DYE SPECTRA
  • Quantum Dots (Continued)
    • TABLE 24 BIOLOGIC IMAGING APPLICATIONS OF QUANTUM DOTS
  • RADIOPHARMACEUTICALS
  • CONTRAST REAGENTS
  • Contrast Reagents (Continued)
  • Contrast Reagents (Continued)
  • EMERGING CLASSES OF IMAGING REAGENTS
  • COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY
    • FIGURE 4 THREE COMPONENTS OF ADVANCED IMAGING
  • REAGENT TECHNOLOGY
  • ADVANCED IMAGING REAGENT FUNCTIONS
    • TABLE 25 EMERGING ADVANCED BIOLOGIC IMAGING REAGENT FUNCTIONS
  • Dual Modality Reagents
  • Multifunctional Reagents
  • Multifunctional Reagents (Continued)
  • Multiplexed Reagents
  • BIOLOGIC IMAGING REAGENTS MANUFACTURING COSTS
    • FIGURE 5 MANUFACTURING COSTS OF IMAGING REAGENT CLASSES
  • BIOLOGIC IMAGING REAGENTS ..... (CONTINUED)
  • COMPARISON OF IMAGING REAGENT TECHNOLOGY PLATFORMS
    • TABLE 26 LIFE CYCLE OF BIOLOGIC IMAGING REAGENT TECHNOLOGIES
    • TABLE 27 TECHNOLOGY STATUS OF BIOLOGIC IMAGING REAGENT PLATFORMS
    • TABLE 28 TECHNOLOGY CHALLENGES FOR IN-VIVO IMAGING REAGENTS
  • COMPARISON OF IMAGING ..... (CONTINUED)

CHAPTER 5: BIOLOGIC IMAGING REAGENTS APPLICATIONS

  • OVERVIEW
    • TABLE 29 BIOLOGIC IMAGING REAGENTS APPLICATIONS
    • TABLE 30 SIGNIFICANCE OF BIOLOGIC IMAGING REAGENTS TO LIFE SCIENCES AND MEDICAL INDUSTRIES
    • TABLE 31 USE OF BIOLOGIC IMAGING REAGENTS BY MARKET SEGMENT
    • TABLE 31 (CONTINUED)
    • TABLE 32 APPLICATIONS WITHIN MARKET SEGMENTS
  • RESEARCH AND DEVELOPMENT
    • TABLE 33 R&D TOOLS
    • TABLE 34 EMERGING APPLICATIONS FOR BIOLOGIC IMAGING REAGENTS IN R&D TOOLS
  • DRUG DISCOVERY AND DEVELOPMENT
    • TABLE 35 DRUG DISCOVERY & DEVELOPMENT
  • INFLUENCE OF IMAGING TECHNOLOGY ON DRUG DEVELOPMENT
  • ATTRITION RATE OF LEAD COMPOUNDS
    • FIGURE 6 ATTRITION RATE OF DRUG CANDIDATES DURING DRUG DEVELOPMENT
  • FLUORESCENT PROTEIN APPLICATIONS IN DRUG DISCOVERY
  • IN-VIVO SMALL ANIMAL IMAGING APPLICATIONS
    • TABLE 36 COMPARISON OF SMALL ANIMAL IMAGING MODALITIES
    • TABLE 37 OUTSTANDING MARKET NEEDS FOR SMALL ANIMAL IMAGING
  • MICRODOSING
  • Biomarkers for Microdosing
    • TABLE 38 BIOMARKERS FOR MICRODOSING
  • Regulatory Requirements for Microdosing
  • Imaging Modalities for Microdosing
    • TABLE 39 MICRODOSING IMAGING MODALITIES
  • Status of Microdosing
  • DIAGNOSTICS
  • INTRODUCTION
    • TABLE 40 DIAGNOSTICS IMAGING REAGENTS APPLICATIONS
    • TABLE 40 (CONTINUED)
  • DIAGNOSTIC APPLICATIONS OF IMAGING REAGENTS
    • TABLE 41 DIAGNOSTIC APPLICATIONS OF SELECTED IMAGING REAGENTS
  • Fluorescent Dyes, Probes and Tags
  • Nanoparticles
  • Supermolecules
  • Imaging Radiopharmaceuticals
  • Contrast Reagents
  • MOLECULAR IMAGING
  • Introduction
    • TABLE 42 CLINICAL APPLICATIONS FOR IN VIVO MOLECULAR IMAGING
  • Optical Molecular Imaging Reagents Status
    • TABLE 43 FLUORESCENCE IMAGING REAGENTS PIPELINE STATUS
  • PET/SPECT Molecular Imaging Reagents Status
    • TABLE 44 PET/SPECT IMAGING REAGENTS PIPELINE STATUS
    • TABLE 44 (CONTINUED)
  • PET/SPECT .....(Continued)
  • Biological Processes Associated with Molecular PET Imaging Reagents
    • TABLE 45 PET IMAGING REAGENT APPLICATIONS
  • Biological Processes ..... (Continued)
  • CASE STUDY: ALZHEIMER' S DISEASE IMAGING REAGENT OPPORTUNITIES
    • FIGURE 7 ALZHEIMER' S DISEASE' S PATHOLOGY PROGRESSION
  • MR IMAGING REAGENTS
    • TABLE 46 EXISTING AND EMERGING MRI IMAGING REAGENTS STATUS
    • TABLE 46 (CONTINUED)
  • ULTRASOUND IMAGING REAGENTS
  • NANOPARTICLES IN DIAGNOSTICS
    • TABLE 47 NANOPARTICLE IN-VIVO DIAGNOSTICS PIPELINE
    • TABLE 48 NANOSPHERE IN-VITRO DIAGNOSTICS REAGENTS PIPELINE
  • HYBRID DIAGNOSTIC/THERAPEUTIC APPLICATIONS
    • TABLE 49 HYBRID IMAGING/THERAPEUTIC APPLICATIONS
  • Hybrid Diagnostic/..... (Continued)

CHAPTER SIX: BIOLOGIC IMAGING REAGENTS INDUSTRY STRUCTURE

  • MEDICAL IMAGING INSTRUMENT INDUSTRY
    • TABLE 50 COMPETITIVE FOCUS OF MAJOR MEDICAL IMAGING COMPANIES
  • INNOVATION WITHIN THE IMAGING REAGENT INDUSTRY
  • ROLE OF CORE IMAGING FACILITIES
  • ROLE OF STRATEGIC ALLIANCES
    • TABLE 51 RECENT IMAGING REAGENT STRATEGIC ALLIANCES
    • TABLE 51 (CONTINUED)
    • TABLE 51 (CONTINUED)
  • Role of Strategic Alliances (Continued)
    • TABLE 52 BIOLOGIC IMAGING REAGENTS INDUSTRY ACQUISITIONS, 2005-2008
    • TABLE 52 (CONTINUED)
    • TABLE 52 (CONTINUED)
    • TABLE 52 (CONTINUED)
  • 2005
  • 2006
  • 2006 (Continued)
  • 2007
  • 2008
  • SPECIALIZED INDUSTRY SECTORS
  • FLUORESCENT DYES AND PROBES
    • TABLE 53 FLUORESCENT DYES AND PROBES KEY COMPETITORS
  • QUANTUM DOTS
    • TABLE 54 QUANTUM DOTS KEY COMPETITORS
    • TABLE 54 (CONTINUED)
  • CONTRAST REAGENTS
    • TABLE 55 CONTRAST REAGENTS KEY COMPETITORS
  • RADIOPHARMACEUTICALS
    • TABLE 56 RADIOPHARMACEUTICALS BIOTECHNOLOGY COMPANIES
  • Radioactive Isotope Supply Industry
  • SMALL ANIMAL IN-VIVO IMAGING
    • TABLE 57 SMALL ANIMAL IN-VIVO FUNCTIONAL IMAGING COMPETITORS
  • CARDIAC IMAGING
    • TABLE 58 CARDIAC IMAGING REAGENT COMPETITIVE SPACE
  • FLUORESCENT PROTEINS
    • TABLE 59 FLUORESCENT PROTEIN PRODUCERS
  • ANTIBODY BIOTECHNOLOGY COMPANIES
    • TABLE 60 ANTIBODY BIOTECHNOLOGY COMPANIES WHO HAVE INTEREST IN IMAGING REAGENTS

CHAPTER SEVEN: BIOLOGIC IMAGING REAGENTS MARKETS

  • GROWTH DRIVING FORCES
    • TABLE 61 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES
  • GROWTH DRIVING FORCES (CONTINUED)
  • INSTRUMENTS MARKETS
    • TABLE 62 GLOBAL VALUE OF INSTRUMENTS AND ASSAYS UTILIZING BIOLOGIC IMAGING REAGENTS, THROUGH 2013 ($ MILLIONS)
    • TABLE 62 (CONTINUED)
  • BIOLOGIC IMAGING REAGENTS MARKETS
  • MARKET OVERVIEW
    • TABLE 63 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY, THROUGH 2013 ($ MILLIONS)
    • TABLE 64 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS MARKET, BY END USE, THROUGH 2013 ($ MILLIONS)
    • TABLE 65 GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY FUNCTION, THROUGH 2013 ($ MILLIONS)
    • TABLE 66 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET, THROUGH 2013 ($ MILLIONS)
    • TABLE 67 GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY MODALITY, THROUGH 2013 ($ MILLIONS)
  • FLUORESCENT PROTEINS
    • TABLE 68 GLOBAL VALUE OF FLUORESCENT PROTEIN REAGENTS, BY TYPE, THROUGH 2013 ($ MILLIONS)
  • NANOPARTICLES
    • TABLE 69 GLOBAL VALUE OF IMAGING NANOPARTICLES BY TECHNOLOGY THROUGH 2013 ($ MILLIONS)
  • CONTRAST REAGENTS
    • TABLE 70 GLOBAL VALUE OF CONTRAST AGENTS MARKET, BY MODALITY, THROUGH 2013 ($ MILLIONS)
    • TABLE 71 GLOBAL VALUE OF MRI REAGENTS MARKET, BY TYPE, THROUGH 2013 ($ MILLIONS)
    • TABLE 72 GLOBAL VALUE OF MRI GD CHELATE REAGENTS, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
    • TABLE 72 (CONTINUED)
  • Contrast Reagents (Continued)
  • Nephrogenic Systemic Fibrosis Impact on Gd-based Contrast Agents
    • TABLE 73 GLOBAL VALUE OF MRI NON-GD CHELATE REAGENTS, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
    • TABLE 74 GLOBAL SALES OF MRI CONTRAST REAGENTS, BY PROCEDURE, THROUGH 2013 ($ MILLIONS)
    • TABLE 75 GLOBAL VALUE OF ULTRASOUND REAGENTS MARKET, BY TYPE, THROUGH 2013 ($ MILLIONS)
    • TABLE 76 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY TYPE, THROUGH 2013 ($ MILLIONS)
  • RADIOPHARMACEUTICALS
    • TABLE 77 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY INDICATION, THROUGH 2013 ($ MILLIONS)
    • TABLE 78 GLOBAL VALUE OF ONCOLOGY RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY INDICATION, THROUGH 2013 ($ MILLIONS)
    • TABLE 79 GLOBAL VALUE OF ONCOLOGY RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
    • TABLE 80 GLOBAL VALUE OF FDG RADIOPHARMACEUTICAL REAGENTS, BY DISEASE CLASS, THROUGH 2013 ($ MILLIONS)
  • OPTICAL IMAGING REAGENTS
    • TABLE 81 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY APPLICATION, THROUGH 2013 ($ MILLIONS)
    • TABLE 82 GLOBAL VALUE OF IN-VITRO RESEARCH AND DRUG DISCOVERY AND DEVELOPMENT OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY, THROUGH 2013 ($ MILLIONS)
    • TABLE 83 GLOBAL VALUE OF GENOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2013 ($ MILLIONS)
    • TABLE 84 GLOBAL VALUE OF PROTEOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2013 ($ MILLIONS)
    • TABLE 85 GLOBAL VALUE OF CELLULAR ANALYSIS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2013 ($ MILLIONS)
    • TABLE 86 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS, BY END USE, THROUGH 2013 ($ MILLIONS)
  • OPTICAL IMAGING REAGENTS (Continued)
    • TABLE 87 GLOBAL VALUE OF IN-VITRO DIAGNOSTIC FLUORESCENT OPTICAL IMAGING REAGENTS, BY MARKET SEGMENT, THROUGH 2013 ($ MILLIONS)
    • TABLE 88 GLOBAL VALUE OF OPTICAL IMAGING REAGENTS, BY TYPE, THROUGH 2013 ($ MILLIONS)
  • GEOGRAPHICAL
    • TABLE 89 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY GEOGRAPHY, THROUGH 2013 ($ MILLIONS)
  • Geographical (Continued)

CHAPTER EIGHT: PATENT STATUS

  • IMAGING REAGENTS PATENTS BY SELECTED TECHNOLOGY
    • TABLE 90 NUMBER OF PATENTS BY TECHNOLOGY
  • FLUORESCENCE REAGENTS
    • TABLE 91 FLUORESCENCE REAGENTS PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
  • FLUORESCENT PROTEINS
    • TABLE 92 FLUORESCENT PROTEIN PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
  • DENDRIMERS
    • TABLE 93 DENDRIMER PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
    • TABLE 94 QUANTUM DOTS PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
  • PATENTS BY COMPANY
    • FIGURE 8 PATENTS BY COMPANY FOR MARKET SEGMENTS
  • LITIGATION STATUS
    • TABLE 95 IP LITIGATION STATUS

CHAPTER NINE: COMPANY PROFILES

  • ACUSPHERE, INC.
    • TABLE 96 ACUSPHERE PRODUCT PIPELINE
    • TABLE 97 ACUSPHERE PATENT ESTATE
    • TABLE 97 (CONTINUED)
  • ADVANCED RESEARCH TECHNOLOGIES INC.
  • AFFIBODY AB
  • AION DIAGNOSTICS
  • ALNIS BIOSCIENCES INC.
  • ALSERES PHARMACEUTICALS INC.
  • AMAG PHARMACEUTICALS
    • TABLE 98 AMAG MOLECULAR IMAGING REAGENTS PIPELINE
    • TABLE 99 AMAG MRI IMAGING REAGENTS MARKETING ALLIANCES
  • ANTICANCER INC
  • AVID RADIOPHARMACEUTICALS
    • TABLE 100 AVID DIAGNOSTIC IMAGING PIPELINE
  • BAYER SCHERING PHARMA AG
  • BBI INTERNATIONAL
  • BD BIOSCIENCES
  • BECKMAN COULTER, INC.
  • BIOFORCE NANOSCIENCES HOLDINGS, INC.
  • BIOMODA INC.
  • BIOPHAN TECHNOLOGIES, INC.
  • BIOSEARCH TECHNOLOGIES, INC.
  • BIOSCEPTRE
  • BIOTAGE AB
  • BRACCO DIAGNOSTICS INC
  • CALIPER LIFE SCIENCES, INC.
  • CAMBRIDGE ISOTOPE LABORATORIES, INC.
  • CAPSULUTION NANOSCIENCES AG
  • CARDINAL HEALTH
  • CARESTREAM HEALTH, INC
  • CELLCYTE GENETICS
  • CHEMICELL GMBH
  • CHINA MEDICAL TECHNOLOGIES, INC.
  • COVIDIEN
  • DENDRITECH, INC.
  • DO-COOP TECHNOLOGIES
  • EBIOSCIENCE, INC.
  • EPIX PHARMACEUTICALS
  • EPIX Pharmaceuticals (Continued)
  • EVIDENT TECHNOLOGIES
  • EVROGEN
  • FERROPHARM GMBH
  • FLUOROPHARMA
    • TABLE 101 FLUORPHARMA PET IMAGING REAGENT PIPELINE
  • FLUOROTECHNICS PTY LTD.
  • Fluorotechnics Pty Ltd (Continued)
  • GE HEALTHCARE
    • TABLE 102 GE HEALTHCARE IMAGING REAGENTS PIPELINE
  • GUERBET
  • IBA MOLECULAR
  • IMMUNICON
  • INDEC BIOSYSTEMS
  • INVITROGEN
  • Invitrogen (Continued)
  • JUBILANT ORGANOSYS LTD
    • TABLE 103 JUBILANT ORGANOSYS MEDICAL IMAGING REAGENT PIPELINE
  • Jubilant Organosys Ltd (Continued)
  • KEREOS, INC.
    • TABLE 104 KEREOS IMAGING REAGENTS PIPELINE
    • TABLE 105 KEREOS STRATEGIC ALLIANCES
  • KPL, INC.
  • LANTHEUS MEDICAL IMAGING
    • TABLE 106 LANTHEUS DIAGNOSTIC IMAGING PIPELINE
  • LUNA NANOWORKS
  • MARINPHARM GMBH
  • MBL INTERNATIONAL
  • MOLECULAR INSIGHT PHARMACEUTICALS
  • MOLECULAR TARGETING TECHNOLOGIES, INC
    • TABLE 107 MTTI IMAGING REAGENTS PIPELINE
  • NANOCO TECHNOLOGIES LTD.
  • NANOPROBES, INC.
  • NANOSPECTRA BIOSCIENCES
  • NANOSPHERE, INC.
    • TABLE 108 NANOSPHERE GOLD IMAGING REAGENTS PIPELINE
  • OXONICA INC.
  • PHILIPS HEALTHCARE
  • PROMEGA CORPORATION
  • SELAH TECHNOLOGIES, LLC
  • SIEMENS AG
  • Siemens AG (Continued)
  • SIGNALOMICS GMBH
  • STARPHARMA HOLDINGS LTD
  • Starpharma Holdings Ltd (Continued)
  • TAKARA BIO INC.
  • THERMO FISHER SCIENTIFIC
  • TK SIGNAL
  • VISEN MEDICAL INC.
  • WILEX AG
    • TABLE 109 WILEX PRODUCT PIPELINE

LIST OF TABLES

  • SUMMARY TABLE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TYPE, THROUGH 2013 ($ MILLIONS)
  • TABLE 1 SCOPE OF THIS REPORT
  • TABLE 2 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY, THROUGH 2013 ($ MILLIONS)
  • TABLE 3 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET, THROUGH 2013 ($ MILLIONS)
  • TABLE 4 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES
  • TABLE 5 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS
  • TABLE 6 BIOLOGIC IMAGING REAGENTS KEY COMPETITORS
  • TABLE 7 KEY BIOLOGIC IMAGING REAGENT TYPES
  • TABLE 8 IN-VIVO IMAGING MODALITIES
  • TABLE 9 COMPARISON OF IN-VIVO IMAGING MODALITIES
  • TABLE 10 APPLICATIONS OF IN-VITRO BIOLOGIC IMAGING
  • TABLE 11 KEY TRENDS FOR IN-VIVO IMAGING
  • TABLE 12 NANOPARTICLES IN IMAGING APPLICATIONS
  • TABLE 13 COMPARISON OF ANTIBODY CONJUGATE NANOPARTICLES
  • TABLE 14 FLUORESCENT DYES AND PROBES
  • TABLE 15 ADVANTAGES OF FLUORESCENCE VERSUS TRADITIONAL METHODS
  • TABLE 16 FLUORESCENT DYE PERFORMANCE CRITERIA
  • TABLE 17 TYPES OF FLUORESCENT PROTEINS
  • TABLE 18 PHOTOACTIVABLE AND PHOTOCONVERTIBLE FLUORESCENT PROTEIN TYPES
  • TABLE 19 EMERGING APPLICATIONS OF FLUORESCENT PROTEINS
  • TABLE 20 FLUORESCENT PROTEINS VERSUS DYES
  • TABLE 21 TECHNOLOGY CHALLENGES FOR FLUORESCENT PROTEINS
  • TABLE 22 CLASSIFICATION OF IMAGING SUPERMOLECULES
  • TABLE 23 COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENT PROTEINS
  • TABLE 24 BIOLOGIC IMAGING APPLICATIONS OF QUANTUM DOTS
  • TABLE 25 EMERGING ADVANCED BIOLOGIC IMAGING REAGENT FUNCTIONS
  • TABLE 26 LIFE CYCLE OF BIOLOGIC IMAGING REAGENT TECHNOLOGIES
  • TABLE 27 TECHNOLOGY STATUS OF BIOLOGIC IMAGING REAGENT PLATFORMS
  • TABLE 28 TECHNOLOGY CHALLENGES FOR IN-VIVO IMAGING REAGENTS
  • TABLE 29 BIOLOGIC IMAGING REAGENTS APPLICATIONS
  • TABLE 30 SIGNIFICANCE OF BIOLOGIC IMAGING REAGENTS TO LIFE SCIENCES AND MEDICAL INDUSTRIES
  • TABLE 31 USE OF BIOLOGIC IMAGING REAGENTS BY MARKET SEGMENT
  • TABLE 32 APPLICATIONS WITHIN MARKET SEGMENTS
  • TABLE 33 R&D TOOLS
  • TABLE 34 EMERGING APPLICATIONS FOR BIOLOGIC IMAGING REAGENTS IN R&D TOOLS
  • TABLE 35 DRUG DISCOVERY & DEVELOPMENT
  • TABLE 36 COMPARISON OF SMALL ANIMAL IMAGING MODALITIES
  • TABLE 37 OUTSTANDING MARKET NEEDS FOR SMALL ANIMAL IMAGING
  • TABLE 38 BIOMARKERS FOR MICRODOSING
  • TABLE 39 MICRODOSING IMAGING MODALITIES
  • TABLE 40 DIAGNOSTICS IMAGING REAGENTS APPLICATIONS
  • TABLE 41 DIAGNOSTIC APPLICATIONS OF SELECTED IMAGING REAGENTS
  • TABLE 42 CLINICAL APPLICATIONS FOR IN VIVO MOLECULAR IMAGING
  • TABLE 43 FLUORESCENCE IMAGING REAGENTS PIPELINE STATUS
  • TABLE 44 PET/SPECT IMAGING REAGENTS PIPELINE STATUS
  • TABLE 45 PET IMAGING REAGENT APPLICATIONS
  • TABLE 46 EXISTING AND EMERGING MRI IMAGING REAGENTS STATUS
  • TABLE 47 NANOPARTICLE IN-VIVO DIAGNOSTICS PIPELINE
  • TABLE 48 NANOSPHERE IN-VITRO DIAGNOSTICS REAGENTS PIPELINE
  • TABLE 49 HYBRID IMAGING/THERAPEUTIC APPLICATIONS
  • TABLE 50 COMPETITIVE FOCUS OF MAJOR MEDICAL IMAGING COMPANIES
  • TABLE 51 RECENT IMAGING REAGENT STRATEGIC ALLIANCES
  • TABLE 52 BIOLOGIC IMAGING REAGENTS INDUSTRY ACQUISITIONS, 2005-2008
  • TABLE 53 FLUORESCENT DYES AND PROBES KEY COMPETITORS
  • TABLE 54 QUANTUM DOTS KEY COMPETITORS
  • TABLE 55 CONTRAST REAGENTS KEY COMPETITORS
  • TABLE 56 RADIOPHARMACEUTICALS BIOTECHNOLOGY COMPANIES
  • TABLE 57 SMALL ANIMAL IN-VIVO FUNCTIONAL IMAGING COMPETITORS
  • TABLE 58 CARDIAC IMAGING REAGENT COMPETITIVE SPACE
  • TABLE 59 FLUORESCENT PROTEIN PRODUCERS
  • TABLE 60 ANTIBODY BIOTECHNOLOGY COMPANIES WHO HAVE INTEREST IN IMAGING REAGENTS
  • TABLE 61 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES
  • TABLE 62 GLOBAL VALUE OF INSTRUMENTS AND ASSAYS UTILIZING BIOLOGIC IMAGING REAGENTS, THROUGH 2013 ($ MILLIONS)
  • TABLE 63 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY, THROUGH 2013 ($ MILLIONS)
  • TABLE 64 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS MARKET, BY END USE, THROUGH 2013 ($ MILLIONS)
  • TABLE 65 GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY FUNCTION, THROUGH 2013 ($ MILLIONS)
  • TABLE 66 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET, THROUGH 2013 ($ MILLIONS)
  • TABLE 67 GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY MODALITY, THROUGH 2013 ($ MILLIONS)
  • TABLE 68 GLOBAL VALUE OF FLUORESCENT PROTEIN REAGENTS, BY TYPE, THROUGH 2013 ($ MILLIONS)
  • TABLE 69 GLOBAL VALUE OF IMAGING NANOPARTICLES BY TECHNOLOGY THROUGH 2013 ($ MILLIONS)
  • TABLE 70 GLOBAL VALUE OF CONTRAST AGENTS MARKET, BY MODALITY, THROUGH 2013 ($ MILLIONS)
  • TABLE 71 GLOBAL VALUE OF MRI REAGENTS MARKET, BY TYPE, THROUGH 2013 ($ MILLIONS)
  • TABLE 72 GLOBAL VALUE OF MRI GD CHELATE REAGENTS, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
  • TABLE 73 GLOBAL VALUE OF MRI NON-GD CHELATE REAGENTS, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
  • TABLE 74 GLOBAL SALES OF MRI CONTRAST REAGENTS, BY PROCEDURE, THROUGH 2013 ($ MILLIONS)
  • TABLE 75 GLOBAL VALUE OF ULTRASOUND REAGENTS MARKET, BY TYPE, THROUGH 2013 ($ MILLIONS)
  • TABLE 76 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY TYPE, THROUGH 2013 ($ MILLIONS)
  • TABLE 77 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY INDICATION, THROUGH 2013 ($ MILLIONS)
  • TABLE 78 GLOBAL VALUE OF ONCOLOGY RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY INDICATION, THROUGH 2013 ($ MILLIONS)
  • TABLE 79 GLOBAL VALUE OF ONCOLOGY RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
  • TABLE 80 GLOBAL VALUE OF FDG RADIOPHARMACEUTICAL REAGENTS, BY DISEASE CLASS, THROUGH 2013 ($ MILLIONS)
  • TABLE 81 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY APPLICATION, THROUGH 2013 ($ MILLIONS)
  • TABLE 82 GLOBAL VALUE OF IN-VITRO RESEARCH AND DRUG DISCOVERY AND DEVELOPMENT OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY, THROUGH 2013 ($ MILLIONS)
  • TABLE 83 GLOBAL VALUE OF GENOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2013 ($ MILLIONS)
  • TABLE 84 GLOBAL VALUE OF PROTEOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2013 ($ MILLIONS)
  • TABLE 85 GLOBAL VALUE OF CELLULAR ANALYSIS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2013 ($ MILLIONS)
  • TABLE 86 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS, BY END USE, THROUGH 2013 ($ MILLIONS)
  • TABLE 87 GLOBAL VALUE OF IN-VITRO DIAGNOSTIC FLUORESCENT OPTICAL IMAGING REAGENTS, BY MARKET SEGMENT, THROUGH 2013 ($ MILLIONS)
  • TABLE 88 GLOBAL VALUE OF OPTICAL IMAGING REAGENTS, BY TYPE, THROUGH 2013 ($ MILLIONS)
  • TABLE 89 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY GEOGRAPHY, THROUGH 2013 ($ MILLIONS)
  • TABLE 90 NUMBER OF PATENTS BY TECHNOLOGY
  • TABLE 91 FLUORESCENCE REAGENTS PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
  • TABLE 92 FLUORESCENT PROTEIN PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
  • TABLE 93 DENDRIMER PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
  • TABLE 94 QUANTUM DOTS PATENT ASSIGNEES BY COMPANY (NUMBER OF PATENTS)
  • TABLE 95 IP LITIGATION STATUS
  • TABLE 96 ACUSPHERE PRODUCT PIPELINE
  • TABLE 97 ACUSPHERE PATENT ESTATE
  • TABLE 98 AMAG MOLECULAR IMAGING REAGENTS PIPELINE
  • TABLE 99 AMAG MRI IMAGING REAGENTS MARKETING ALLIANCES
  • TABLE 100 AVID DIAGNOSTIC IMAGING PIPELINE
  • TABLE 101 FLUORPHARMA PET IMAGING REAGENT PIPELINE
  • TABLE 102 GE HEALTHCARE IMAGING REAGENTS PIPELINE
  • TABLE 103 JUBILANT ORGANOSYS MEDICAL IMAGING REAGENT PIPELINE
  • TABLE 104 KEREOS IMAGING REAGENTS PIPELINE
  • TABLE 105 KEREOS STRATEGIC ALLIANCES
  • TABLE 106 LANTHEUS DIAGNOSTIC IMAGING PIPELINE
  • TABLE 107 MTTI IMAGING REAGENTS PIPELINE
  • TABLE 108 NANOSPHERE GOLD IMAGING REAGENTS PIPELINE
  • TABLE 109 WILEX PRODUCT PIPELINE

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TYPE, 2006-2013 ($ MILLIONS)
  • FIGURE 1 MOLECULAR ENGINEERING OF DENDRIMER IMAGING SUPERMOLECULES
  • FIGURE 2 QUANTUM DOT SPECTRA
  • FIGURE 3 FLUORESCENT DYE SPECTRA
  • FIGURE 4 THREE COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY
  • FIGURE 5 MANUFACTURING COSTS OF IMAGING REAGENT CLASSES
  • FIGURE 6 ATTRITION RATE OF DRUG CANDIDATES DURING DRUG DEVELOPMENT
  • FIGURE 7 ALZHEIMER' S DISEASE' S PATHOLOGY PROGRESSION
  • FIGURE 8 PATENTS BY COMPANY FOR MARKET SEGMENTS
Back to Top